About Diplomat Pharmacy (NYSE:DPLO)
Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems. The company's primary focus is on medication management programs for individuals with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious or long-term conditions. The company was founded in 1975 and is headquartered in Flint, Michigan.
Industry, Sector and Symbol
Industry Drug stores & proprietary stores
Sub-IndustryN/A
SectorRetail/Wholesale
SymbolNYSE:DPLO
CUSIPN/A
Phone888-720-4450
Debt
Debt-to-Equity Ratio0.70%
Current Ratio0.97%
Quick Ratio0.66%
Price-To-Earnings
Trailing P/E Ratio25.61
Forward P/E Ratio22.43
P/E GrowthN/A
Sales & Book Value
Annual Sales$4.49 billion
Price / Sales0.34
Cash Flow$1.7875 per share
Price / Cash11.67
Book Value$10.88 per share
Price / Book1.92
Profitability
EPS (Most Recent Fiscal Year)$0.84
Net Income$15.51 million
Net Margins0.35%
Return on Equity8.89%
Return on Assets4.47%
Miscellaneous
Employees2,419
Outstanding Shares74,070,000
Diplomat Pharmacy (NYSE:DPLO) Frequently Asked Questions
What is Diplomat Pharmacy's stock symbol?
Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."
How were Diplomat Pharmacy's earnings last quarter?
Diplomat Pharmacy (NYSE:DPLO) announced its quarterly earnings data on Monday, February, 26th. The company reported $0.18 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.16 by $0.02. The firm had revenue of $1.16 billion for the quarter, compared to analysts' expectations of $1.17 billion. Diplomat Pharmacy had a return on equity of 8.89% and a net margin of 0.35%. Diplomat Pharmacy's revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.08 earnings per share. View Diplomat Pharmacy's Earnings History.
When is Diplomat Pharmacy's next earnings date?
What guidance has Diplomat Pharmacy issued on next quarter's earnings?
Diplomat Pharmacy issued an update on its FY18 earnings guidance on Monday, February, 26th. The company provided earnings per share guidance of $0.87-0.97 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.02. The company issued revenue guidance of $5.3-5.6 billion, compared to the consensus revenue estimate of $5.48 billion.
What price target have analysts set for DPLO?
11 brokers have issued 12 month target prices for Diplomat Pharmacy's stock. Their forecasts range from $17.00 to $35.00. On average, they anticipate Diplomat Pharmacy's share price to reach $25.50 in the next twelve months. View Analyst Ratings for Diplomat Pharmacy.
Who are some of Diplomat Pharmacy's key competitors?
Some companies that are related to Diplomat Pharmacy include Tech Data (TECD), PriceSmart (PSMT), Groupon (GRPN), Jack in the Box (JACK), Lithia Motors (LAD), Li-Ning (LNNGY), Dominos Pizza UK & IRL (DPUKY), Boohoo.com (BHOOY), Bed Bath & Beyond (BBBY), The Cheesecake Factory (CAKE), Signet Jewelers (SIG), Tempur Sealy International (TPX), Greene King (GKNGY), Builders FirstSource (BLDR), Bloomin' Brands (BLMN), Travelport (TVPT), At Home (HOME) and The Children's Place (PLCE).
Who are Diplomat Pharmacy's key executives?
Diplomat Pharmacy's management team includes the folowing people:
- Mr. Philip R. Hagerman, Co-Founder & Chairman Emeritus (Age 66)
- Mr. Gary Rice M.B.A., M.S., R.Ph., RPh, MS, MBA, CSP, Exec. VP of Operations (Age 60)
- Mr. Jeffrey G. Park, Interim CEO & Director (Age 46)
- Mr. Joel Saban, Pres (Age 50)
- Mr. Atul Kavthekar, CFO, Treasurer & Principal Accounting Officer
Has Diplomat Pharmacy been receiving favorable news coverage?
Media headlines about DPLO stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Diplomat Pharmacy earned a daily sentiment score of 0.14 on Accern's scale. They also assigned news coverage about the company an impact score of 44.39 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
How do I buy shares of Diplomat Pharmacy?
Shares of DPLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Diplomat Pharmacy's stock price today?
One share of DPLO stock can currently be purchased for approximately $20.97.
How big of a company is Diplomat Pharmacy?
Diplomat Pharmacy has a market capitalization of $1.59 billion and generates $4.49 billion in revenue each year. The company earns $15.51 million in net income (profit) each year or $0.84 on an earnings per share basis. Diplomat Pharmacy employs 2,419 workers across the globe.
How can I contact Diplomat Pharmacy?
Diplomat Pharmacy's mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The company can be reached via phone at 888-720-4450 or via email at [email protected]
MarketBeat Community Rating for Diplomat Pharmacy (DPLO)
MarketBeat's community ratings are surveys of what our community members think about Diplomat Pharmacy and other stocks. Vote "Outperform" if you believe DPLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DPLO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Diplomat Pharmacy (NYSE:DPLO) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
11 Wall Street analysts have issued ratings and price targets for Diplomat Pharmacy in the last 12 months. Their average twelve-month price target is $25.50, suggesting that the stock has a possible upside of 22.24%. The high price target for DPLO is $35.00 and the low price target for DPLO is $17.00. There are currently 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Buy | Hold |
| Consensus Rating Score: | 2.45 | 2.45 | 2.50 | 2.17 |
| Ratings Breakdown: | 0 Sell Rating(s)
6 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
8 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $25.50 | $25.50 | $20.5625 | $19.1563 |
| Price Target Upside: | 22.24% upside | 21.26% upside | 10.56% downside | 9.85% downside |
Diplomat Pharmacy (NYSE:DPLO) Consensus Price Target History
Diplomat Pharmacy (NYSE:DPLO) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
Diplomat Pharmacy (NYSE:DPLO) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Diplomat Pharmacy (NYSE DPLO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 30.20%
Institutional Ownership Percentage: 63.73%
Diplomat Pharmacy (NYSE DPLO) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/9/2018 | Philip R. Hagerman | Director | Sell | 2,150,000 | $20.65 | $44,397,500.00 | |  |
| 11/20/2017 | Atul Kavthekar | CFO | Buy | 2,000 | $15.00 | $30,000.00 | 2,000 | |
| 11/20/2017 | Jeffrey G Park | Director | Buy | 3,000 | $15.46 | $46,380.00 | 7,640 | |
| 11/20/2017 | Joel Saban | President | Buy | 10,000 | $15.24 | $152,400.00 | 12,000 | |
| 9/15/2016 | Atheer A Kaddis | EVP | Sell | 20,000 | $30.12 | $602,400.00 | 20,000 | |
| 8/1/2016 | Atheer A Kaddis | EVP | Sell | 12,325 | $35.76 | $440,742.00 | 12,325 | |
| 7/1/2016 | Atheer A Kaddis | EVP | Sell | 12,325 | $35.04 | $431,868.00 | 12,325 | |
| 6/1/2016 | Atheer A Kaddis | EVP | Sell | 12,325 | $32.31 | $398,220.75 | 12,325 | |
| 5/2/2016 | Atheer A Kaddis | EVP | Sell | 12,325 | $30.17 | $371,845.25 | 12,325 | |
| 4/15/2016 | Atheer A Kaddis | EVP | Sell | 24,650 | $30.00 | $739,500.00 | 24,650 | |
| 2/12/2016 | Atheer A. Kaddis | EVP | Sell | 12,325 | $30.00 | $369,750.00 | | |
| 12/7/2015 | Philip R Hagerman | CEO | Sell | 2,300,000 | $33.60 | $77,280,000.00 | | |
| 12/1/2015 | Atheer A. Kaddis | SVP | Sell | 12,325 | $34.75 | $428,293.75 | | |
| 12/1/2015 | Gary W. Kadlec | President | Sell | 30,000 | $34.93 | $1,047,900.00 | | |
| 11/3/2015 | Atheer A. Kaddis | SVP | Sell | 24,650 | $30.00 | $739,500.00 | | |
| 11/2/2015 | Gary W. Kadlec | President | Sell | 30,000 | $28.03 | $840,900.00 | | |
| 10/1/2015 | Gary W. Kadlec | President | Sell | 30,000 | $27.66 | $829,800.00 | | |
| 9/8/2015 | Atheer A. Kaddis | SVP | Sell | 12,325 | $37.42 | $461,201.50 | | |
| 9/1/2015 | Gary W. Kadlec | President | Sell | 30,000 | $38.05 | $1,141,500.00 | | |
| 8/26/2015 | Sean Whelan | CFO | Sell | 149,534 | $38.04 | $5,688,273.36 | 142,530 | |
| 3/25/2015 | David C Dreyer | Director | Buy | 1,034 | $29.00 | $29,986.00 | | |
| 3/25/2015 | Jeffrey M Rowe | EVP | Sell | 600,000 | $29.00 | $17,400,000.00 | | |
| 3/25/2015 | Philip R Hagerman | CEO | Sell | 1,801,000 | $29.00 | $52,229,000.00 | | |
| 10/9/2014 | Atheer A Kaddis | SVP | Buy | 4,000 | $13.00 | $52,000.00 | | |
| 10/9/2014 | Jeffrey M Rowe | EVP | Sell | 416,666 | $13.00 | $5,416,658.00 | | |
| 10/9/2014 | Philip R Hagerman | CEO | Sell | 2,916,666 | $13.00 | $37,916,658.00 | | |
| 10/9/2014 | Sean Whelan | CFO | Buy | 2,000 | $13.00 | $26,000.00 | | |
(Data available from 1/1/2013 forward)
Diplomat Pharmacy (NYSE DPLO) News Headlines
| Source: |
|
Diplomat Pharmacy (NYSE:DPLO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Diplomat Pharmacy (NYSE:DPLO) Income Statement, Balance Sheet and Cash Flow Statement
Diplomat Pharmacy (NYSE DPLO) Stock Chart for Thursday, April, 19, 2018
Loading chart…
